<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03488654</url>
  </required_header>
  <id_info>
    <org_study_id>Heart-SLE</org_study_id>
    <nct_id>NCT03488654</nct_id>
  </id_info>
  <brief_title>CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography</brief_title>
  <official_title>The Heart in Systemic Lupus Erythematosus - a Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In systemic lupus erythematosus (SLE), cardiac manifestations, e.g. coronary artery disease&#xD;
      (CAD) and myocarditis are leading causes of morbidity and mortality. The prevalence of&#xD;
      subclinical heart disease in SLE is unknown. We studied whether a comprehensive&#xD;
      cardiovascular magnetic resonance (CMR) protocol may be useful for early diagnosis of heart&#xD;
      disease in SLE patients without known CAD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitement problems as single centre study&#xD;
  </why_stopped>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of cardiovascular pathologies identified by CMR in patients with SLE</measure>
    <time_frame>at baseline</time_frame>
  </primary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Disease</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiovascular magnetic resonance</intervention_name>
    <description>CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with diagnosed SLE&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of SLE, as defined by the American College of Rheumatology Classification&#xD;
             Criteria for Systemic Lupus Erythematosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age under 18 years&#xD;
&#xD;
          -  known coronary artery disease&#xD;
&#xD;
          -  impaired renal function with an estimated glomerular filtration rate less than 30&#xD;
             ml/min, estimated by the Modification of Diet in Renal Disease Study Group (MDRD)&#xD;
             formula (45)&#xD;
&#xD;
          -  devices as pacemakers, implantable cardioverter-defibrillators, insulin pumps and&#xD;
             others&#xD;
&#xD;
          -  metallic foreign bodies in the eyes, ferromagnetic implants labeled MR unsafe&#xD;
&#xD;
          -  allergy against CMR contrast media or adenosine&#xD;
&#xD;
          -  presence of chronic atrial fibrillation, 2nd or 3rd degree Atrioventricular&#xD;
             (AV)-block, trifascicular block, asthma and severe chronic obstructive pulmonary&#xD;
             disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thilo Burkard</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

